GBIO Generation Bio Co. Stock Quote

GBIO [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	4.20%	Shs Outstand	45.47M	Perf Week	11.05%
Market Cap	2.06B	Forward P/E	-	EPS next Y	-2.04	Insider Trans	-2.47%	Shs Float	27.40M	Perf Month	45.42%
Income	-	PEG	-	EPS next Q	-0.50	Inst Own	79.90%	Short Float	5.77%	Perf Quarter	-11.49%
Sales	-	P/S	-	EPS this Y	-71.30%	Inst Trans	36.37%	Short Ratio	2.62	Perf Half Y	40.31%
Book/sh	6.30	P/B	6.08	EPS next Y	27.90%	ROA	-	Target Price	39.25	Perf Year	-
Cash/sh	5.21	P/C	7.35	EPS next 5Y	-	ROE	-	52W Range	17.00 - 55.72	Perf YTD	35.06%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-32.43%	Beta	-
Dividend %	-	Quick Ratio	31.20	Sales past 5Y	-	Gross Margin	-	52W Low	121.47%	ATR	3.41
Employees	85	Current Ratio	31.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	56.90	Volatility	11.86% 10.00%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-76.00%	Profit Margin	-	Rel Volume	0.16	Prev Close	38.29
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	603.97K	Price	37.65
Recom	1.50	SMA20	9.84%	SMA50	18.47%	SMA200	32.64%	Volume	7,844	Change	-1.67%

Feb-24-21

Initiated

William Blair

Outperform

Feb-18-21

Initiated

Needham

Buy

$50

Jul-07-20

Initiated

Wedbush

Outperform

$31

Jul-07-20

Initiated

JP Morgan

Overweight

$28

Jul-07-20

Initiated

Jefferies

Buy

$38

Jul-07-20

Initiated

Cowen

Outperform

Mar-01-21 08:53AM	Why Earnings Season Could Be Great for Generation Bio (GBIO) Zacks +15.12%
Feb-18-21 10:02AM	Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2021 Benzinga
07:30AM	Generation Bio Appoints Ron Cooper to Its Board of Directors GlobeNewswire
Jan-13-21 11:29PM	Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares Simply Wall St.
Jan-11-21 05:43PM	Generation Bio Announces Closing of Public Offering GlobeNewswire
Jan-06-21 09:24PM	Generation Bio Announces Pricing of Public Offering GlobeNewswire
Jan-05-21 08:44AM	Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1% Zacks -17.22%
06:30AM	Generation Bio to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-04-21 06:30AM	Generation Bio Announces Two Non-Viral Gene Therapy Milestone Achievements: Target Levels of Factor VIII Expression in Hemophilia A Mice and Translation of Expression from Mice to Non-Human Primates GlobeNewswire +6.10%
Dec-13-20 03:52AM	Need To Know: Generation Bio Co. (NASDAQ:GBIO) Insiders Have Been Buying Shares Simply Wall St.
Dec-02-20 11:34PM	Is Generation Bio (GBIO) A Good Stock To Buy Now? Insider Monkey +6.59%
Nov-10-20 06:30AM	Generation Bio Reports Third Quarter 2020 Business Updates and Financial Results GlobeNewswire
Oct-31-20 08:00AM	Kaskela Law LLC Announces Stockholder Investigation of Generation Bio Co. - GBIO ACCESSWIRE
Oct-05-20 06:30AM	Generation Bio to Present at 2020 Virtual Cell & Gene Meeting on the Mesa GlobeNewswire +7.22%
Sep-24-20 06:30AM	Generation Bio to Present at the Jefferies 2020 Virtual Gene Therapy/Editing Summit GlobeNewswire
Sep-14-20 10:59AM	Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +7.90%
Aug-11-20 06:30AM	Generation Bio Reports Business Updates and Second Quarter 2020 Financial Results GlobeNewswire
Aug-05-20 06:30AM	Generation Bio to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
Jul-22-20 07:00AM	Generation Bio Appoints Matthew Norkunas, M.D., MBA as Chief Financial Officer GlobeNewswire
Jun-16-20 04:02PM	Generation Bio Announces Closing of Initial Public Offering GlobeNewswire -12.15%
Jun-12-20 12:31PM	Generation Bio shares soar 23% in trading debut MarketWatch
06:24AM	Generation Bio prices upsized IPO at $19 a share to raise $199.5 million MarketWatch
Jun-11-20 09:52PM	Generation Bio Announces Pricing of Initial Public Offering GlobeNewswire

Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Feb 10	Option Exercise	0.60	10,400	6,240	208,554	Feb 12 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Feb 10	Sale	34.60	10,400	359,856	198,154	Feb 12 04:05 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Feb 08	Option Exercise	4.59	11,267	51,716	337,825	Feb 10 04:05 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Feb 08	Sale	33.37	11,267	375,954	326,558	Feb 10 04:05 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Feb 02	Option Exercise	4.59	2,500	11,475	2,500	Feb 04 04:05 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Feb 02	Sale	33.05	2,500	82,625	0	Feb 04 04:05 PM
Angelino Mark D.	CHIEF OPERATING OFFICER	Jan 15	Option Exercise	4.59	7,500	34,425	353,137	Jan 20 04:05 PM
Angelino Mark D.	CHIEF OPERATING OFFICER	Jan 15	Sale	32.97	7,500	247,273	345,637	Jan 20 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Jan 14	Option Exercise	0.60	5,630	3,378	203,784	Jan 15 04:05 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Jan 14	Option Exercise	4.59	2,500	11,475	2,500	Jan 15 04:06 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Jan 14	Sale	33.09	2,500	82,725	0	Jan 15 04:06 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Jan 14	Sale	32.54	5,630	183,212	198,154	Jan 15 04:05 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Jan 11	Option Exercise	4.59	11,267	51,716	337,825	Jan 13 04:07 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Jan 11	Option Exercise	0.60	14,820	8,892	212,974	Jan 13 04:06 PM
Rowland Charles A Jr	Director	Jan 11	Buy	24.50	20,408	499,996	101,035	Jan 13 04:04 PM
Nicholson Donald William	Director	Jan 11	Buy	24.50	4,081	99,985	103,157	Jan 13 04:05 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Jan 11	Sale	27.58	11,267	310,768	326,558	Jan 13 04:07 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Jan 11	Sale	27.69	14,820	410,372	198,154	Jan 13 04:06 PM
Angelino Mark D.	Chief Operating Officer	Dec 15	Option Exercise	4.59	5,301	24,332	350,938	Dec 17 04:05 PM
Angelino Mark D.	Chief Operating Officer	Dec 15	Sale	34.98	5,301	185,431	345,637	Dec 17 04:05 PM
Stanton Matthew	Chief Scientific Officer	Dec 10	Option Exercise	0.60	10,540	6,324	208,694	Dec 14 04:05 PM
Stanton Matthew	Chief Scientific Officer	Dec 10	Sale	37.62	10,540	396,499	198,154	Dec 14 04:05 PM
Angelino Mark D.	Chief Operating Officer	Aug 14	Option Exercise	0.60	62,560	37,536	345,637	Aug 18 04:07 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience